文献速递神经头颈MR

脑膜瘤MR成像中降低钆剂量的比较评估:剂量能低到多少?

Comparative Evaluation of Lower Gadolinium Doses for MR Imaging of Meningiomas: How Low Can We Go?
PubMed 文献 · AJNR Am J Neuroradiol · 2024-11-07

研究纳入108例疑似或确诊脑膜瘤患者,按钆剂量分为微剂量(约标准剂量25%)、低剂量(约标准剂量62%)和标准剂量三组,多阅片者视觉评估显示低剂量对标准剂量非劣效,而微剂量在肿瘤与皮层及静脉窦区分上的次优比例显著高于标准剂量。结论认为降至标准剂量62%仍可充分勾画脑膜瘤,进一步降至25%则明显影响鉴别能力,故不可取。

要点

  • 低剂量(约标准剂量62%)视觉评估对标准剂量非劣效,可满足脑膜瘤与周围组织的勾画。
  • 微剂量(约标准剂量25%)与标准剂量相比,肿瘤与皮层区分次优比例显著更高(P=.041)。
  • 微剂量与标准剂量相比,肿瘤与静脉窦区分次优比例显著更高(P<.001)。

核心结论

  • 将钆剂量降至标准剂量的62%仍可充分视觉勾画脑膜瘤与周围组织;进一步降至25%则明显损害肿瘤与邻近结构的区分能力,因此不可取。

研究设计与样本

  • 研究纳入108例疑似或确诊脑膜瘤并于多剂量钆剂下行脑MRI的患者,按钆剂量分为微剂量(约标准剂量25%)、低剂量(约标准剂量62%)和标准剂量三组,采用多阅片者定性视觉评估与定量相对信号差异计算,定量用ANOVA、定性用McNemar检验,并对低剂量和微剂量与标准剂量作非劣效检验。

诊断标准与关键数值

  • 微剂量(约标准剂量25%)与标准剂量相比,肿瘤与皮层区分次优比例显著更高(P=.041)。
  • 微剂量(约标准剂量25%)与标准剂量相比,肿瘤与静脉窦区分次优比例显著更高(P<.001)。
  • 低剂量(约标准剂量62%)在视觉评估中对标准剂量非劣效。
  • 降低钆剂量至低剂量或微剂量时,肿瘤与邻近脑组织的信号差异出现统计学显著下降(P<.02)。

临床应用与阅片要点

  • 作者结论认为,将钆剂量降至标准剂量的62%仍可充分视觉勾画脑膜瘤与周围组织。
  • 作者结论认为,进一步将钆剂量降至标准剂量的25%会明显损害肿瘤与邻近结构的区分能力,因此不可取。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Gadolinium-based contrast agents are widely used for meningioma imaging; however, concerns exist regarding their side effects, cost, and environmental impact. At the standard gadolinium dose, most meningiomas show avid contrast enhancement, suggesting that administering a smaller dose may be feasible. The purpose of this study was to evaluate the impact of a lower gadolinium dose on the differentiation between meningiomas and adjacent intracranial tissues.

MATERIALS AND METHODS: One hundred eight patients with presumed or confirmed meningiomas who underwent a brain MRI at multiple doses of gadolinium were included in the study. The patients' MRIs were categorized into 3 groups based on the gadolinium dose administered: micro (approximately 25% of the standard dose), low (approximately 62% of the standard dose), and standard dose. Multireader qualitative visual assessment and quantitative relative signal differences calculations were performed to evaluate tumor differentiation from the cortex and from the dural venous sinus. The relative signal differences for each dose were analyzed by using ANOVA for quantitative assessment and the McNemar test for qualitative assessment. Additionally, noninferiority testing was used to compare the low and micro doses to the standard dose.

RESULTS: Decreasing the gadolinium dose to a low dose or micro dose resulted in a statistically significant decrease in signal difference between the tumor and the adjacent brain tissue (P < .02). However, on visual assessment, the low dose was noninferior to the standard dose. The proportion of cases with suboptimal differentiation was significantly higher for the micro dose than for the standard dose, both for the differentiation between the tumor and the cortex (P = .041) and the differentiation between the tumor and the sinus (P < .001).

CONCLUSIONS: Reducing the gadolinium dose to 62% of the standard level still allows for sufficient visual delineation of meningiomas from surrounding tissues. However, further reduction to 25% substantially compromises the ability to distinguish the tumor from adjacent structures and is, therefore, not advisable.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Dowers T, Helmi A, Mbanwi AN, et al. Comparative Evaluation of Lower Gadolinium Doses for MR Imaging of Meningiomas: How Low Can We Go? AJNR Am J Neuroradiol. 2024. PMID: 38858096. doi:10.3174/ajnr.A8375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。